New drug research and development project stakes in biopharmaceuticals: Lilly tirzepatide topped the list.

EP Vantage, a globally renowned life sciences industry consulting firm, recently released a report predicting the most valuable new drug development projects in the biopharmaceutical sector.
01, Tirzepatide Is a gastric inhibitor peptide (GIP)/glucagon-like peptide-1 (GLP-1) dual receptor agonising agent, developed by Lilly, also topped last year's most valuable TOP10 research and development project.
ADA 2019 data show that in patients with type 2 diabetes, tirzepatide improves beta cell function and insulin sensitivity markers, significantly lowers blood sugar levels and weight, improves gastrointestinal side effects, and improves non-alcoholic fatty hepatitis markers.
currently, tirzepatide is currently clinically developed in Phase III for sugar reduction and weight loss.
Lilly is comparing tirzepatide with the GLP-1 receptor agonisant Trulicity in head-to-head III SURPASS-CVOT trials.
from the available data, multi-receptor agonists are more effective than single GLP-1 receptor agonists in terms of sugar reduction and weight loss.
in China, Lilly has submitted 18 clinical trials covering type 2 diabetes, type 2 diabetes combined with high-risk cardiovascular risk and obesity.
, according to Evaluate's forecast, the drug will sell for $2,198 million in 2026.
02, Inclisiran this drug is the first siRNA cholesterol-lowering drug, targeting PCSK9, Novartis through the $9.4 billion acquisition of TMC.
currently on the market, two PCSK9 targeted drugs are on the market, amin Repatha and Sanofi/Regenerative Praluent.
these two monotorsis work by targeting the PCSK9 protein, and inclisiran directly shuts down the production of PCSK9 protein in the liver.
Inclisiran is expected to be approved for the second half of this year, based on strong cholesterol-lowering efficacy and the benefits of two subcutaneous administrations a year, the drug will have a huge impact on the two monotonicas, with Evaluate's 2026 sales forecast to reach $2.01 billion.
03, Efgartigimod, developed by Argenx, is a pioneering anti-FcRn antibody fragment, developed using ABDEG technology, targeted in combination with IgG recovery receptor FcRn, to prevent IgG recovery, so that IgG faster depletion, promote IgG removal.
currently, efgartigimod has been developed to treat a variety of severe autoimmune diseases mediated by high-level pathogenic IgG.
at the end of May this year, the drug treats AChR antibody-positive systemic severe muscle weakness (gMG) key Phase III ADAPT study was successful.
based on this data, Argenx plans to submit a listing application by the end of the year.
the industry is very bullish on the drug's prospects, with Evaluate forecasting sales of $2,002 million for 2026.
the drug is also one of the few drugs developed by small companies on top 10.
04, BMS-986165 The drug was developed by BMS, is a new, oral, selective TYK2 inhibitor with a unique mechanism different from other listed kinase inhibitors.
TYK2 is an intracellular signaling kinase that mediates cytokine-driven immune and pro-inflammatory signaling pathways that play a vital role in the chronic inflammatory cycle of immune-mediated diseases.
currently, BMS-986165 is clinically developed in Stage III for the treatment of psoriasis and a variety of autoimmune diseases.
in the deal to acquire the new base, BMS sold otezla, another oral anti-inflammatory drug, under antitrust requirements, and the company now has high hopes for BMS-986165 to recover the potential psoriasis franchise losses from the sale of Otezla.
, according to Evaluate's forecast, the drug will have sales of $1.81 billion in 2026.
05, ALN-HBV02 The drug was developed by Vir Biotechnology and is an RNAi treatment for hepatitis B that inhibits the expression of all HBV proteins, including hepatitis B surface antigens (HBsAg).
viral protein knockout may help the patient's own immune response to HBV, providing a potential functional cure for chronic HBV patients.
ALN-HBV02 is administered by subcutaneous injection, effectively silence all HBV RNA transcripts, which are necessary for HBV replication and viral protein expression.
ALN-HBV02 is developed using Alnylam's latest ESC-GalNAc conjugate technology, which makes subcutaneous administration more potent and persistent, with a broad treatment index. Givlaari, the first RNAi drug to be used in the
, has been approved for sale in the US and Europe, and Novartis inclisiran has adopted the technology, which in part provides confidence in the success of ALN-HBV02.
Evaluate forecasts sales of $1.164 billion in 2026.
06, Aducanumab The drug was developed by YanJian in collaboration with Eiwood, is a single anti-drug targeting beta amyloid protein for the treatment of Alzheimer's disease (AD).
early July, the two sides completed the application for biological products licensing to the U.S. FDA.
if approved, aducanumab would be the first treatment that meaningfully alters the AD process and slows the decline of AD clinical condition, and the first to demonstrate that the removal of beta amyloid protein can yield better clinical results.
highly anticipated, the drug is also controversial.
topped the list of most valuable TOP10 new drugs in 2018, but slipped to sixth place in last year's TOP10 list, with the net present value falling by half to $5,361 million, and this year's sixth place, unchanged.
partly reflects the industry's uncertainty about the drug's prospects.
07, Belantamab Mafodotin, developed by GlaxoSmithKline, is an antibody drug conjugate (ADC) that targets B-cell maturation antigens (BCMA) to treat recurrent or refractive multiple myeloma that has previously been treated with multiple treatments.
is currently under review by US and EU regulators.
mid-July, the drug was approved by the FDA's Cancer Medicine Advisory Board (12-0).
BCMA is a popular immuno-oncology target for malignant tumors in the blood system.
if approved, the drug would be the first BCMA-targeted therapy to be available.
Evaluate's forecast selling of the drug will reach $1.251 billion in 2026.
08, LN-144 The drug was developed by Iovance Biotherapeutics, an autonomous tumor-immersed lymphocyte (TIL) therapy that is currently being clinically developed in Phase II to treat a variety of solid tumors.
in the body, TIL migrates to the tumor when the cancer occurs and attacks the tumor.
However, usually the number of Tilses in the patient's body is not sufficient to eliminate the tumor, and the tumor microenvironment inhibits the function of the TIL.
the drug is based on the patient's own TIL, the preparation process includes: the acquisition of tumor tissue from the patient's body and the extraction of TIL, in vitro using IL-2 cytokine to stimulate TIL amplification, the method can not only increase the number of TIL, but also activate the til anti-tumor ability.
the tints are then fed back into the patient's body, enabling more effective killing of tumor cells.
at the 2019 ASCO annual meeting, the drug treats the total remission rate of metastatic or stubborn cervical cancer by 44% and the total remission rate of 11%.
, according to Evaluate's forecast, the drug will generate sales of $1,473 million in 2026.
09, AK002 The drug developed by Allakos, is a target salivary acid combined with immunoglobulin-like coagulation 8 (SIGLEC-8) monoantisay, for the treatment of eosinophils and hypertrophy-related diseases.
SIGLEC-8 is a class of inhibitory receptors expressed in eosinophils and hypertrophic cells, and the erroneous activation of these two cells has been shown to be a key driver of a range of diseases, and AK002 is able to inhibit hypertrophic cells and consume eophilic cells through SIGLEC-8.
currently, the drug treats etoice gastritis (EG) and/or eodicliitis (EoD) has entered Phase III clinical, the treatment of eosinophilic esophagitis (EoE) into Phase II/III clinical.
an EG/EoD long-term open label extension study released in May showed that up to 94 percent of patients had improved disease histological symptoms.
Evaluate's forecast selling of $1.201 billion in 2026.
10, Risdiplam, a drug developed by Roche to treat spinal muscular dystrophy (SMA).
this is an oral liquid, motor neuron survival gene 2 (SMN2) splicing modifier designed to continuously increase and maintain SMN protein levels in the central nervous system and peripheral tissues.
the drug was developed for the treatment of all three types of SMA and is currently under FDA priority review with a target action date of August 24 this year.
if approved, the drug would be the first oral SMA drug.
, according to Evaluate's forecast, the drug will have sales of $1.412 billion in 2026.
Source: Top 10 Most Valuable R and D Projects (Rank ed by Net Value Value)